Details of the Drug Combination

General Information of Drug Combination (ID: DCPHL38)

Drug Combination Name
ARRY-162 Brigatinib
Indication
Disease Entry Status REF
ALK Gene Rearrangement Phase 1 [1]
Component Drugs ARRY-162   DM1P6FR Brigatinib   DM7W94S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ARRY-162
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [2]
ARRY-162 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
MAPK/ERK kinase kinase (MAP3K) TTROQ37 NOUNIPROTAC Modulator [5]
ERK activator kinase (MEK) TTZCRP3 NOUNIPROTAC Inhibitor [2]
------------------------------------------------------------------------------------
ARRY-162 Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [6]
------------------------------------------------------------------------------------
ARRY-162 Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [7]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Indication(s) of Brigatinib
Disease Entry ICD 11 Status REF
Anaplastic large cell lymphoma 2A90.A Approved [3]
Non-small-cell lung cancer 2C25.Y Approved [4]
Brigatinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Brigatinib Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
ATP-binding cassette sub-family B member 5 (ABCB5) DTKVEXO ABCB5_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Brigatinib Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04005144) Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
2 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
5 MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
6 The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391.
7 FDA Label of Binimetinib. The 2020 official website of the U.S. Food and Drug Administration.
8 Binimetinib - European Medicines Agency - European Union
9 NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA.
10 Brigatinib: first global approval. Drugs. 2017 Jul;77(10):1131-1135.